Establishment Labs Holdings Inc. filings document regulatory disclosures for a British Virgin Islands medical technology issuer listed on Nasdaq. Its Form 8-K reports cover operating results and financial condition, preliminary financial information, Regulation FD presentation materials, credit-agreement amendments, senior secured term-loan obligations, and other material definitive agreements.
The company’s proxy materials disclose board matters, executive compensation, equity awards, shareholder voting items, and governance practices. Together, the filings describe the Motiva-focused breast aesthetics and reconstruction business, capital structure, debt arrangements, forward-looking-statement disclosures, and recurring corporate reporting obligations.
Establishment Labs Holdings Inc. entered into a fourth amendment to its credit agreement with Oaktree Fund Administration. The amendment makes the Tranche D term loans available as of the amendment’s effective date, removing the need to first achieve the revenue milestone originally required. It also raises the minimum liquidity the company and its guarantor subsidiaries must maintain from $25,000,000 to $30,000,000, effective September 28, 2025.
On the same day, the company fully drew the available Tranche D term loans, resulting in a new borrowing of $25,000,000 under the credit agreement. The amendment itself is filed as an exhibit to provide full details of the revised terms.
Edward J. Schutter, a director of Establishment Labs Holdings Inc. (ESTA), received 457 common shares as payment in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy. The shares were issued under the Issuer’s 2018 Equity Incentive Plan and were valued based on the closing market price used to determine the share equivalent. After this issuance the reporting person beneficially owns 138,015 shares, held directly.
Establishment Labs Holdings Inc. (ESTA) director Ann Custin acquired 503 common shares on 09/30/2025 at a price of $40.99 per share. The shares were issued under the company’s 2018 Equity Incentive Plan and were elected in lieu of a quarterly cash retainer under the issuer’s Outside Director Compensation Policy; the number of shares was determined using the closing price on the last trading day of the quarter. Following the transaction, the reporting person beneficially owned 21,087 shares. The Form 4 was signed by the company’s CFO by power of attorney on 10/01/2025.
Establishment Labs Holdings director Nicholas Sheridan reported acquiring 609 common shares on 09/30/2025 at a price of $40.99 per share. These shares were issued under the company’s 2018 Equity Incentive Plan and represent shares elected to be received in lieu of a quarterly cash retainer under the issuer’s Outside Director Compensation Policy.
After the transaction the reporting person directly beneficially owned 1,076,532 shares. An additional 19,090 shares are noted as indirectly beneficially owned via the reporting person’s spouse. The Form 4 discloses this routine director compensation election and does not show derivative transactions.
Reporting person: Leslie Gillin, a director of Establishment Labs Holdings Inc. (ESTA), acquired common shares as director compensation.
Transaction details: On 09/30/2025 the reporting person received 411 common shares issued under the company's 2018 Equity Incentive Plan at an effective price of $40.99 per share, representing shares elected in lieu of a quarterly cash retainer. Following the issuance the reporting person beneficially owned 15,516 common shares directly. The transaction was reported on Form 4 and signed by power of attorney on 10/01/2025.
JW Asset Management, JW Partners, JW Opportunities Fund, JW GP and Jason G. Wild reported writing and selling 940 call options on Establishment Labs Holdings Inc. (ESTA) on 08/22/2025. Each option contract covers 100 shares, so the transaction represents rights on 94,000 shares with a $42.50 strike and an option price of $2.1802 per share. The reported position shows 94,000 underlying shares associated with the calls and is held indirectly through affiliated entities. The filing identifies the advisor and affiliated entities as joint reporting persons and explains their relationships.
Establishment Labs Holdings director Nicholas Sheridan Lewin reported an indirect open-market purchase of 2,600 common shares of ESTA on August 14, 2025 at $37.85 per share. The acquired shares are held by his spouse, with Lewin reporting indirect beneficial ownership of 19,090 shares and direct ownership of 1,075,923 shares.
Capital Research Global Investors reports beneficial ownership of 1,024,417 shares of Establishment Labs Holdings Inc., equal to 3.5% of 28,917,254 shares outstanding. The filing states that CRGI is a division of Capital Research and Management Company and related investment management entities that provide services under the name "Capital Research Global Investors." CRGI reports sole voting power and sole dispositive power over the 1,024,417 shares.
The filing further certifies the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing is categorized as an investment adviser (Type: IA).
ESTABLISHMENT LABS HOLDINGS INC. director Lewin Nicholas Sheridan reported an open-market purchase of 2,300 common shares at an average price of $34.2955 per share. The newly purchased shares are held indirectly through his spouse. Following this transaction, he reports direct ownership of 1,075,923 common shares and an additional 16,490 shares held indirectly.
Filippo Caldini, who is listed as Chief Executive Officer and a director of Establishment Labs Holdings Inc. (ESTA), reported a purchase of common shares on 08/11/2025. The amended Form 4/A shows a purchase of 2,850 common shares at $35.20 per share, resulting in reported beneficial ownership of 35,245 shares. The transaction is reported with code P and the ownership is listed as direct (D).
The filing is an amendment (Form 4/A) submitted by a single reporting person and was signed on behalf of the reporting person by Rajbir S. Denhoy, Chief Financial Officer, by power of attorney. The document does not state total outstanding shares or the percentage that 35,245 shares represent, so the filing alone does not establish the transaction's materiality to shareholders.